During the weekly meeting of President Miguel Diaz-Canel with the scientific community, the director of the Finlay Vaccine Institute, Vicente Verez, revealed that this project is different, with the same antigen, but using another platform.
Referring to the effectiveness of this new immunizer, Verez noted, ‘it is giving very interesting answers and we are going to move it quickly.’
Cuba announced on August 19 the start of clinical trials of Soberana 01, a vaccine candidate against Covid-19 made in the country, which was approved for Phase I/II studies by the Center for State Control of Medicines, Equipment and Medical Devices (CECMED).
The process started on August 24 and will end on January 11, 2021, and covers 676 people between 19 and 80 years old.
The research to develop the immunizing drug will be carried out in a randomized, controlled, adaptive and multicenter manner aimed to assess the safety, reactogenicity and immunogenicity of the candidate in a two-dose schedule.